Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment

The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) fo...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-04, Vol.9 (1), p.5916-5916, Article 5916
Main Authors: Guo, Renyong, Xie, Yirui, Yang, Jiezuan, Lu, Haifeng, Ye, Ping, Jin, Linfeng, Lin, Wenqin
Format: Article
Language:English
Subjects:
13/21
14/63
631/250/127/98
692/308/53
692/4020/4021/234
96/21
ADAM protein
ADAMTS13 Protein - genetics
ADAMTS13 Protein - metabolism
Adult
Antiviral Agents - therapeutic use
Antiviral drugs
Deoxyribonucleic acid
DNA
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B e Antigens - blood
Hepatitis B e Antigens - immunology
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B, Chronic - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Humanities and Social Sciences
Humans
Interferon
Liver
Male
multidisciplinary
Multivariate analysis
Patients
ROC Curve
Science
Science (multidisciplinary)
Seroconversion
Seroconversion - drug effects
Thrombospondin
Viral Load
Von Willebrand factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) for CHB patients during 5-year entecavir (ETV) treatment. One hundred and fourteen HBeAg positive CHB patients on continuous ETV treatment were recruited. Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively. ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-019-42421-5